以肺栓塞严重指数评分为依据对中危患者进行抗凝治疗疗效及可行性评价(1)
[摘要] 目的 探究對中危肺栓塞患者进行抗凝治疗的疗效，并且对其可行性进行评价。 方法 方便选取2014年3月—2018年3月间来贵阳医院呼吸科接受住院治疗的肺栓塞患者64例进行该次的实验研究，所有的患者经肺栓塞严重指数评分为中度危险患者(Ⅲ级和Ⅳ级)每一级患者各有32例，在患者出院后用华法林治疗3个月，患者的治疗无明显差异。而后分析不同级别患者抗凝治疗的临床疗效、心肌损伤指标、血气分析以及患者的出血情况。 结果 Ⅲ级患者总有效率为96.88%，显著高于Ⅳ级患者75.00%，差异有统计学意义(P<0.05);治疗后，Ⅲ级患者二氧化碳分压、氧分压、动脉血氧饱和度、脑钠肽、肌钙蛋白Ⅰ分别为：(25.5±1.3)mmHg、(85.2±3.1)mmHg、(91.2±3.1)%、(126.51±15.42)pg/mL、(1.34±0.24)ng/mL，均显著优于对照组(t=19.028、26.188、25.982、22.985、21.983，P<0.05);治疗后，Ⅲ级患者发生出血3.13%，显著低于Ⅳ级9.37%(χ2=8.874，P=0.025<0.05)。 结论 由此可知，根据肺栓塞严重指数评分来为中危肺栓塞患者提供抗凝治疗具有更加明显的效果，更加安全，对患者预后具有一定的指导作用。
, 百拇医药
[关键词] 肺栓塞严重指数;中危患者;抗凝治疗;疗效;可行性评价
[中图分类号] R5 [文献标识码] A [文章编号] 1674-0742(2019)08(b)-0079-04
[Abstract] Objective To investigate the efficacy of anticoagulant therapy in patients with moderate-risk pulmonary embolism and evaluate its feasibility. Methods Sixty-four patients with pulmonary embolism who were admitted to the Department of Respiratory Medicine of Guiyang Hospital from March 2014 to March 2018 were conveniently selected in this study. All patients underwent pulmonary embolism severity index as moderately dangerous patients (Class III and Class IV). There were 32 patients in each class. After the patients were discharged from hospital， they were treated with warfarin for 3 months. There was no significant difference in the treatment of the patients. Then， the clinical efficacy， myocardial injury index， blood gas analysis and bleeding of patients with different levels of anticoagulant therapy were analyzed. Results The total effective rate of class III patients was 96.88%， which was significantly higher than that of class IV patients， 75.00%， the difference was significant(P<0.05). After treatment， class III patients with carbon dioxide partial pressure， oxygen partial pressure， arterial oxygen saturation， brain natriuretic peptide troponin I was(25.5±1.3)mmHg，(85.2±3.1)mmHg，(91.2±3.1)%， (126.51±15.42)pg/mL，(1.34±0.24)ng/mL， which were significantly better than the control group(t=19.028， 26.188， 25.982， 22.985， 21.983 ，P<0.05); after treatment， class III patients developed 3.13% of bleeding， which was significantly lower than IV level 9.37%(χ2=8.874， P=0.025<0.05). Conclusion From this we can know that the anticoagulant therapy for patients with moderate-risk pulmonary embolism according to the severity index of pulmonary embolism has a more obvious effect， is safer， and has a certain guiding effect on the prognosis of patients., 百拇医药(黄家胜 付英转 许蓉 罗倩 闵捷 谢本艳)
, 百拇医药
[关键词] 肺栓塞严重指数;中危患者;抗凝治疗;疗效;可行性评价
[中图分类号] R5 [文献标识码] A [文章编号] 1674-0742(2019)08(b)-0079-04
[Abstract] Objective To investigate the efficacy of anticoagulant therapy in patients with moderate-risk pulmonary embolism and evaluate its feasibility. Methods Sixty-four patients with pulmonary embolism who were admitted to the Department of Respiratory Medicine of Guiyang Hospital from March 2014 to March 2018 were conveniently selected in this study. All patients underwent pulmonary embolism severity index as moderately dangerous patients (Class III and Class IV). There were 32 patients in each class. After the patients were discharged from hospital， they were treated with warfarin for 3 months. There was no significant difference in the treatment of the patients. Then， the clinical efficacy， myocardial injury index， blood gas analysis and bleeding of patients with different levels of anticoagulant therapy were analyzed. Results The total effective rate of class III patients was 96.88%， which was significantly higher than that of class IV patients， 75.00%， the difference was significant(P<0.05). After treatment， class III patients with carbon dioxide partial pressure， oxygen partial pressure， arterial oxygen saturation， brain natriuretic peptide troponin I was(25.5±1.3)mmHg，(85.2±3.1)mmHg，(91.2±3.1)%， (126.51±15.42)pg/mL，(1.34±0.24)ng/mL， which were significantly better than the control group(t=19.028， 26.188， 25.982， 22.985， 21.983 ，P<0.05); after treatment， class III patients developed 3.13% of bleeding， which was significantly lower than IV level 9.37%(χ2=8.874， P=0.025<0.05). Conclusion From this we can know that the anticoagulant therapy for patients with moderate-risk pulmonary embolism according to the severity index of pulmonary embolism has a more obvious effect， is safer， and has a certain guiding effect on the prognosis of patients., 百拇医药(黄家胜 付英转 许蓉 罗倩 闵捷 谢本艳)